SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is actively discussed following its recent European Commission approval for the oncology drug ANKTIVA and a new distribution partnership spanning 33 countries. The community is buzzing with strong bullish sentiment, anticipating a significant short squeeze driven by these global expansion catalysts and substantial short interest.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending after its earnings revealed robust revenue growth but a net loss, primarily due to higher loan loss provisions, which has led to a significant stock decline. While many in the community view it as a broken IPO with a questionable business model, others are aggressively buying the dip, confident in its strong user expansion and strategic market position within the struggling fintech sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

The FDA's decision to review Moderna's seasonal flu vaccine application is driving investor optimism and a notable share price surge, while community sentiment remains highly active, weighing this regulatory win against its expanding oncology pipeline and a significant patent infringement trial.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to a competitor's recent regulatory setback and patent loss for its Cushing's syndrome treatment, which the community views as removing a significant competitive threat for Xeris's Recorlev and creating an irrational dip-buying opportunity. Investors are actively discussing the strong market position and growth potential of Recorlev and the upcoming earnings report, despite the stock's recent price action.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co. is experiencing a significant rally following an earnings report that surpassed expectations and included raised guidance, with management signaling a bottoming of the agriculture cycle. However, community sentiment is sharply divided, as many question the sustainability of the surge given concerns about declining revenue, high debt, and valuation, while others celebrate the "homerun" and anticipate further upside.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma (FIG) is rallying after beating Q4 earnings and issuing strong guidance, with community sentiment shifting to view its strategic AI partnerships as a growth driver rather than a disruption. High short interest is fueling intense volatility as investors re-evaluate the broader SaaS sector's AI narrative.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is a hot topic after its Q4 earnings, which, despite beating estimates, presented conservative forward guidance, sparking debate on its high valuation and a significant new $30 billion share buyback program amidst strong e-commerce and AI growth.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending after its strong earnings beat, increased dividend, and announced 25-for-1 stock split surprisingly resulted in a significant sell-off. Community discussion is heavily focused on whether AI poses a genuine disruptive threat to the travel sector, particularly with Google's expanded AI travel tools, or if market concerns are overstated.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space (FJET) is trending on the heels of its upcoming NYSE Opening Bell ceremony, sparking intense community speculation around a potential short squeeze due to its tight float, with many anticipating significant gains as the space sector heats up ahead of the highly anticipated Space X IPO.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

Medical Properties Trust (MPT) is trending as its recent earnings report and strategic actions have energized a community bullish on its turnaround story, with aggressive call buying and high short interest fueling intense discussions about a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.57) earnings per share for the quarter, missing...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down Following Weak Earnings...

Madrigal Pharmaceuticals Q4 Earnings Call Highlights

Madrigal Pharmaceuticals (NASDAQ:MDGL) highlighted a near-$1 billion first full year of net sales for Rezdiffra during its fourth quarter and full year 2025 earnings call, while emphasizing...

Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of -7,442.86% and +2.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ raised its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 361.6% in the third quarter, according to the company in its most recent...

What to Expect From These Drug/Biotech Players This Earnings Season?

Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.

Principal Financial Group Inc. Purchases 2,862 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Principal Financial Group Inc. raised its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 31.1% in the third quarter, according to its most recent Form 13F filing...

Madrigal Pharmaceuticals is Now Oversold (MDGL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

MDGL Strengthens MASH Franchise With New Genetic Approaches 

Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.

Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

$MDGL Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$2.57 up 5.17% YoY
• Reported revenue of $321.08M up 210.77% YoY
• Madrigal expects robust net sales growth for Rezdiffra in 2026, driven by broad first-line access and increasing disease awareness, further solidifying its market leadership position in MASH treatment.

Stocktwits

Madrigal Pharmaceuticals Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$2.57 up 5.17% YoY
• Reported revenue of $321.08M up 210.77% YoY
• Madrigal expects robust net sales growth for Rezdiffra in 2026, driven by broad first-line access and increasing disease awareness, further solidifying its market leadership position in MASH treatment.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Despite robust Rezdiffra sales exceeding $1 billion, the company's significant Q4 loss of $2.57 per share due to soaring SG&A expenses has concerned investors.

With Rezdiffra sales reaching $1 billion and projections for robust double-digit growth through 2026 and beyond, many anticipate multi-billion dollar revenue in the coming years.

Traders are eyeing support levels around $400-$460, believing current dips present a "senseless drop" and a strong buying opportunity for a long-term hold.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.00	-$2.57	-158.00%	MISSED
Q3 '25	-$2.29	-$5.08	-122.31%	MISSED
Q2 '25	-$3.55	-$1.90	46.54%	BEAT
Q1 '25	-$3.75	-$3.32	11.43%	BEAT
Q4 '24	-$3.84	-$2.71	29.34%	BEAT

MDGL
Madrigal Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest MDGL News

MDGLMadrigal Pharmaceuticals Inc